



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Klock et al.

Serial No.: 10/582,279

Filed: December 10, 2004

Title: Anti-Apoptotically Active Aptamers

Group Art Unit: To be assigned

Examiner: To be assigned

I hereby certify that this paper (or fee) is being deposited with the United States Postal Service, first class postage prepaid, addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

September 25, 2006

James P. Zeller
Reg. No. 28,491

INFORMATION DISCLOSURE STATEMENT

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

The documents listed on the enclosed Form PTO-1449 are identified pursuant to 37 CFR §§ 1.56, 1.97, and 1.98. Copies of the documents are enclosed as required.

U.S. 2005/0222020 is an English language equivalent of DE 101 63 130 A1.

Entry and consideration of the submitted documents are solicited.

Respectfully submitted,

MARSHALL, GERSTEIN & BORUN LLP

September 25, 2006

By: James P. Zeller
Reg. No. 28,491
Attorneys for Applicants
Customer No. 04743
6300 Sears Tower
233 South Wacker Drive
Chicago, Illinois 60606-6357
(312) 474-6300



Form PTO-1449 (Modified) INFORMATION DISCLOSURE STATEMENT	U.S. Department of Commerce Patent and Trademark Office		Atty. Docket No. 31113/C720	Serial No. 10/582,279
	Applicant Klock et al.			
	Filing Date June 9, 2006		Group	

U.S. PATENT DOCUMENTS							
*Examiner Initials		Document Number	Publication Date	Name	Class	Subclass	Filing Date if Appropriate
		US 2005/022020	10/6/2005	Freyberg, et al.	514	12	

FOREIGN PATENT DOCUMENTS								
*Examiner Initials		Document Number	Publication Date	Country	Class	Subclass	Translation	
							Yes	No
		DE 101 63 130	10/6/2005	Germany			X	
		WO 03/054009	07/03/03	PCT				
		WO 02/26932	04/04/02	PCT				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)	
	Agrawal, "Antisense Oligonucleotides Towards Clinical Trials," <i>Tibtech</i> , vol. 14, pp. 376-387, October, 1996
	Cerchia et al., "Nucleic Acid Aptamers in Cancer Medicine," <i>FEBS Letters</i> , vol. 528, pp. 12-16, August 28, 2002
	Ellington et al., "Aptamers as Potential Nucleic Acid Pharmaceuticals," <i>Biotechnology Annual Review</i> , vol. 1, pp. 185-214, 1995
	Famulok, "Oligonucleotide Aptamers that Recognize Small Molecules," pp. 324-329
	Freyberg et al., "Proatherogenic Flow Conditions Initiate Endothelial Apoptosis via Thrombospondin-1 and the Integrin-Associated Protein," <i>Biochemical and Biophysical Research Communications</i> , vol. 286, pp. 141-149, 2001
	Gold et al., "Diversity of Oligonucleotide Functions," <i>Annu. Rev. Biochem.</i> , vol. 64, pp. 763-797, 1995
	Jayasena, "Aptamers: An Emerging Class of Molecules that Rival Antibodies in Diagnostics," <i>Clinical Chemistry</i> , vol. 45, no. 9, pp. 1628-1650, 1999
	Köhler et al., "Continuous Cultures of Fused Cells Secreting Antibody of Predefined Specificity," <i>Nature</i> , vol. 256, pp. 495-497, 1975
	Osborne et al., "Nucleic Acid Selection and the Challenge of Combinatorial Chemistry," <i>Chem. Rev.</i> , vol. 97, pp. 349-370, 1997
	Pieken et al., "Kinetic Characterization of Ribonuclease-Resistant 2'-Modified Hammerhead Ribozymes," <i>Science</i> , vol. 253, pp. 314-317, July 19, 1991
	Ruckman et al., "2'-Fluoropyrimidine RNA-Based Aptamers to the 165-Amino Acid Form of Vascular Endothelial Growth Factor (VEGF 165)," <i>The Journal of Biological Chemistry</i> , vol. 273, no. 32, pp. 20556-20567, August 7, 1998
	The Eyetech Study Group, "Preclinical and Phase 1A Clinical Evaluation of an Anti-

		VEGF Pegylated Aptamer (EYE001) for the Treatment of Exudative Age-Related Macular Degeneration,” <i>The Journal of Retinal and Vitreous Diseases</i> , vol. 22, no. 2, pp. 143-151, 2002
--	--	---

Examiner	Date Considered
<p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	